Author Archives: Kyle Habet

Virtually Perfect? Telemedicine for Covid-19

Recognizing that patients prioritize convenient and inexpensive care, in-person visits should become the second, third, or even last option for meeting patient needs.Previous work has specifically described the potential for using telemedicine in disasters and public health emergencies.

The BCG Vaccine – Are we protected?

In Belize and in many developing countries we are vaccinated with the BCG vaccine a few days to weeks after birth. An interesting observation is being made amidst the COVID-19 pandemic. In these countries, the number of severe cases is comparably low compared to countries that do administer the BCG vaccine.

New Symptoms Emerging for COVID-19

A study in Europe has found that loss of taste and loss of smell have been reported in patients with confirmed COVID-19 infections and may sometimes precede classical symptoms such as cough and fever. Neurologic signs such as impaired consciousness and skeletal muscle injury have also been reported in another study.

Update on Hydroxychloroquine

Update on Hydroxychloroquine.

The latest study finds no benefit from hydroxychloroquine. Hydroxycholorquine was heralded as a potential game-changer for treating COVID-19. However, a new study shows that the drug is of little benefit.[1] This does not mean it should be written off as a potential treatment option. It has shown antiviral activity in-vitro and the rationale for its use is plausible. More evidence is still needed and clinical trials are still ongoing.